SecBot SecBot
8-K ·Filed May 29, 2026

JAZZ

Jazz Pharmaceuticals plc
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001628280-26-039147
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No trading action warranted. Monitor the 2026 proxy statement for any board composition changes or new director nominees, but this single departure is immaterial to JAZZ's fundamentals or near-term outlook.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
JAZZ ▲ +12.56% at T+60d
NEUTRAL call +12.56% · α vs SPY +11.59% · entry $231.19 → $260.23
Entry = T+0 close
May 29, 2026
via day close
T+1d
-2.19%
call -2.19% · α -2.34%
$226.12
settled 5mo ago
T+5d
+3.19%
call +3.19% · α +5.94%
$238.57
settled 5mo ago
T+20d
+2.82%
call +2.82% · α +5.14%
$237.72
settled 4mo ago
T+60d
+12.56%
call +12.56% · α +11.59%
$260.23
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Director Anne O'Riordan informed Jazz Pharmaceuticals' board that she will not stand for re-election at the 2026 annual meeting. The filing explicitly states her decision was not due to any dispute or disagreement with the company. This is a routine board refreshment event with no material impact on operations or strategy.

Key Facts

  • Anne O'Riordan, a Class III director, will not stand for re-election at the 2026 annual meeting
  • Decision was not the result of any dispute or disagreement with the company or board
  • Board will continue to evaluate composition and facilitate orderly succession
  • No replacement named in the filing

Financial Impact

No financial impact — routine director departure with no compensation or operational changes disclosed

Risk Factors

  • Potential loss of board expertise if O'Riordan's departure is not offset by a qualified replacement

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (24 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-039147
Document: 0001628280-26-039147-index-headers.html0001628280-26-039147
Document: 0001628280-26-039147-index.html0001628280-26-039147
Document: 0001628280-26-039147.txt0001628280-26-039147
28 reports for JAZZ
Performance horizon
60% Hit rate @ T+1 3 of 5 directional calls Went positive at some point 4 of 5 best @ T+60▲ +22.04%Feb 24, 2026
Filters
Rows
Reports for JAZZ — sortable, filterable
TypeNow
Oct 19, 2026
6d ago
Press Release
NEUTRAL ★ 1/10
$213.76 $211.97▼ −0.84%▼ −1.36%$210.99 (−1.30%)
Oct 9, 2026
17d ago
8-K
NEUTRAL ★ 2/10
$218.42 $216.75▼ −0.76%▼ −0.70%$210.99 (−3.40%)
Oct 8, 2026
17d ago
144
NEUTRAL ★ 2/10
$218.42 $216.75▼ −0.76%▼ −0.70%$210.99 (−3.40%)
Oct 6, 2026
19d ago
144
NEUTRAL ★ 2/10
$231.19 $222.45▼ −3.78%▼ −3.36%$210.99 (−8.74%)
Oct 1, 2026
24d ago
144
NEUTRAL ★ 2/10
$235.67 $236.04▲ +0.16%▼ −0.52%$210.99 (−10.47%)
Sep 15, 2026
5w ago
8-K
BULLISH ★ 6/10
$240.83 $243.59▲ +1.15%▲ +1.59%$210.99 (−12.39%)
Sep 14, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$240.83 $243.59▲ +1.15%▲ +1.59%$210.99 (−12.39%)
Sep 10, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$245.80 $245.87▲ +0.03%▲ +0.47%$210.99 (−14.16%)
Sep 2, 2026
7w ago
Insider Cluster
BEARISH ★ 4/10
$247.57 $246.81▲ +0.30%▼ −0.08%$210.99 (+14.78%)
Aug 31, 2026
7w ago
144
NEUTRAL ★ 2/10
$243.71 $245.57▲ +0.76%▲ +0.32%$210.99 (−13.43%)
Showing 10 of 28

US Market Status

Market Open — Closes in 5h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026